Edwards Lifesciences said net sales for 2024 were $5.4 billion, an increase of $429.5 million from 2023, driven by sales growth of TAVR and TMTT products.

1. 01

   Edwards Lifesciences said net sales for 2024 were $5.4 billion, an increase of $429.5 million from 2023, driven by sales growth of TAVR and TMTT products.

2. 02

   The company completed the sale of its Critical Care product group to Becton, Dickinson and Company in an all-cash transaction for $4.2 billion on September 3, 2024, and recorded a $3.3 billion pre-tax gain on the sale in discontinued operations.

3. 03

   Edwards Lifesciences said operating cash flow for 2024 was $542.3 million, a decrease of $353.5 million from 2023, citing as factors tax payments of $1.2 billion (including $469.7 million related to the Critical Care sale and tax deposits of $305.1 million).

4. 04

   The company said it repurchased 16.7 million shares for an aggregate cost of $1.2 billion under the Board of Directors authorized program in 2024, and as of December 31, 2024 had remaining authority to purchase $1.4 billion of common stock.

Key figures

Fiscal year ended December 31, 2024

Revenue

$5.4B

Operating income

$1.4B

Net income

$4.2B

EPS

$6.97

Gross profit

$4.3B

Operating cash flow

$542M

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.